Medications

Rituximab, mycophenolate mofetil compared for pemphigus vulgaris

(HealthDay)—For patients with pemphigus vulgaris, rituximab is superior to mycophenolate mofetil for producing sustained complete remission at 52 weeks, according to a study published online May 19 in the New England Journal ...

Diseases, Conditions, Syndromes

Lowering urine protein aids renal function in rare kidney disease

(HealthDay)—Reducing urinary protein aids patients with the rare kidney disease focal segmental glomerulosclerosis (FSGS), according to a study published online Aug. 10 in the American Journal of Kidney Diseases.

HIV & AIDS

Existing drugs may limit damage caused by HIV

Yale researchers have identified four drugs that may help minimize the long-term health effects of HIV infection, they report June 23 in the Journal of Clinical Investigation.

Immunology

Use of stem cells, conditioning induces immune tolerance

(HealthDay) -- A novel approach using a bioengineered mobilized cellular product enriched with hematopoietic stem cells (HSCs) and tolerogenic graft facilitating cells (FCs) in combination with nonmyeloablative conditioning ...

Medications

Recommendations developed for atopic dermatitis therapies

In updated guidelines issued by the American Academy of Dermatology and published online Nov. 7 in the Journal of the American Academy of Dermatology, recommendations are presented for use of phototherapy and systemic therapies ...

Diseases, Conditions, Syndromes

Transplant drug helpful for patients with progressive liver condition

New research indicates that mycophenolate mofetil, a drug that is usually used to prevent rejection after kidney, heart or liver transplant, seems safe and effective in treating autoimmune hepatitis (AIH), a serious chronic ...

page 2 from 3